CD20 antigen is expressed on the surface of >90% of B-cell Non-Hodgkin's Lymphomas (NHL). Binding to CD20 antigen is necessary for the antitumor effect of Rituxan.
Whole blood or bone marrow
* This volume does not allow for repeat testing
Refrigerated samples
Frozen samples
Clotted samples
Reference ranges are provided on report as general guidance only.
CD20 antigen is expressed on the surface of >90% of B-cell Non-Hodgkin's Lymphomas (NHL). Binding to CD20 antigen is necessary for the antitumor effect of Rituxan.
48 to 72 hours
01396586
86356